GAMMA Investing LLC has raised its stake in
Danaher Co., while
Everence Capital Management Inc. has sold a significant number of shares.
Scotiabank initiated coverage of
Danaher with a Sector Perform recommendation, and
Baron Health Care Fund added the firm to its portfolio.
Jim Cramer of Mad Money expressed high regard for Danaher, describing it as a vital position despite its lackluster performance and unimpressive guidance in Q3, where China’s core revenue diminished.
Charles Akre suggests Danaher proves to be a worthy long-term investment, and the corporation displays resilience and growth potential amidst market challenges. Danaher reported strong Q3 earnings, surpassing estimates, with increased diagnostics sales year over year. Its life sciences business also drove Q2 success, calling attention of hedge funds. Controversially,
Parnassus Growth Equity Fund divested from Danaher, and some experts suggest avoiding investing in Danaher's stock right now. Danaher has prevalent reliance on international sales, posing interest to investors. The corporation submitted SEC Form 8-K, providing leadership and financial updates.
Danaher Corporation DHR News Analytics from Tue, 23 Apr 2024 07:00:00 GMT to Sat, 04 Jan 2025 09:21:41 GMT -
Rating 5
- Innovation 3
- Information 8
- Rumor 4
